FUDANZHANGJIANG (01349.HK): Bladder Cancer Drug NDA Accepted in China
NewTimeSpace News: On 19 November 2026, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (stock code: 01349.HK) said it received an acceptance notice from the NMPA for its abbreviated new drug application for aminolevulinic acid hydrochloride granules, developed for intraoperative visualization of non-muscular invasive bladder cancer.
The drug has a strength of 1.5 g per sachet and is filed as a class 3 chemical drug for domestic manufacturing and marketing authorization, under acceptance number CYHS2602848. The company obtained clinical trial approval in February 2024 and started a Phase III confirmatory trial in March 2025 to evaluate the efficacy and safety of oral administration for fluorescence-guided tumour resection; the trial has been completed.
NMIBC accounts for about 75% of bladder cancer cases, and transurethral resection of bladder tumour is the preferred surgical treatment, with residual tumour a major cause of recurrence, the company said. Approval remains subject to technical review, on-site inspection and administrative approval, and the timing and outcome are uncertain; the acceptance is not expected to have a material impact on near-term results.
- BRAINAURORA-B (06681.HK): DELIGHT Study Shows Brain-Heart Mechanism
- FUDANZHANGJIANG (01349.HK): 2026 interim results, profit attributable to shareholders of RMB 36.895 million, up 545.57% year on year
- FUDANZHANGJIANG (01349.HK): Invests RMB270 Million in Ping An Bank Structured Deposit to Enhance Capital Returns
- Fudan-Zhangjiang (01349.HK): Invests RMB 330 Million in Structured Deposits of Ping An Bank
- India Announces Time-Limited Zero Tariff! Chinaamc Msci India Etf (03404.HK) Rebounds in Afternoon Trading, Surging Over 1.5%